5 results
To compare prostate-specific antigen (PSA) progression-free survival (PFS) failure rates during long-term treatment with 3-monthly subcutaneous (s.c.) injections of degarelix or goserelin in prostate cancer patients (PSA PFS failure is defined as…
Primary Objective - To evaluate the time to PSA >4 ng/mL during the first cycle of IAD after the end of an induction period with degarelix (7 monthly treatments) in prostate cancer patientsSecondary Objectives - To evaluate the time to PSA .4…
The purpose of the study is to collect long-term data of safety, tolerability, and efficacy to support the submission of marketing authorisation of one-month dosing regimen of degarelix for treatment of prostate cancer.Primary Objective:•To evaluate…
Phase Ia: (dose escalation):- To determine the maximum tolerated dose (MTD) and a recommended Phase II dose (RP2D) for M3814 (also referred to as MSC2490484A) in combination with fractionated palliative radiotherapy (RT) for tumors or metastases…
The objective of this trial is to collect additional safety data.The further objective of this trial is to collect long-term efficacy measures as well as to assess the treatment effect on:- disability and productivity- functional impairment- health-…